BPDCN is an aggressive hematologic malignancy with a historically poor prognosisVisualDx is a clinical decision support system used by more than ...

Marlise R. Luskin, MD, MSCE, discussed treatment options for blastic plasmacytoid dendritic cell neoplasm (BPDCN), a rare and challenging disease.

The Menarini Group, along with its subsidiary Stemline Therapeutics, has announced a partnership with VisualDx to enhance the ...

Moffitt Cancer Center researchers have discovered a promising new vaccine strategy for treating a specific type of breast ...

An expert discusses how medical professionals have integrated tagraxofusp into blastic plasmacytoid dendritic cell neoplasm ...

If you've ever noticed how memories from the same day seem connected while events from weeks apart feel separate, a new study ...

The BPDCN cell of origin is the plasmacytoid dendritic cell (pDC) precursor. The diagnosis of BPDCN is based on the immunophenotypic diagnostic triad of CD123, CD4, and CD56, as well as other markers.

VisualDx is a clinical decision support system used by more than 2,300 hospitals, clinics, and medical schools around the world VisualDx's system seeks to enhance identification of people who may ...